• Episode #11: Professor Allan Bradley - Founder and CEO of T-Therapeutics

  • Mar 2 2025
  • Durée: 43 min
  • Podcast

Episode #11: Professor Allan Bradley - Founder and CEO of T-Therapeutics

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • Today, we’re excited to welcome Allan Bradley to Gravity Encounters. As the Founder and CEO of T-Therapeutics, Allan has had a profound impact on the fields of genomics, monoclonal antibody discovery, and biotech entrepreneurship.

    Previously, as the Director of the Wellcome Trust Sanger Institute, Allan played a pivotal role in transforming its genome-sequencing infrastructure into a world-class research centre. His academic research laid the foundation for Kymab Ltd, a humanised antibody discovery company that led to the development of novel therapeutic antibodies, some of which have demonstrated clinical benefits.

    Beyond Kymab, Allan co-founded PetMedix, applying cutting-edge antibody technologies to animal health. Earlier in his career, he spun out Lexicon Genetics while at Baylor College of Medicine, which went on to a $1 billion NASDAQ debut within just five years. A Fellow of the Royal Society and an expert in mouse genetics, Allan has significantly shaped the biotech landscape.

    Today, we’ll explore Allan’s journey, from academia to building billion-dollar companies, and the scientific and entrepreneurial insights he’s gained along the way.

    Hosts: Emily James and Jan Venne
    Voir plus Voir moins
Voir plus Voir moins

Ce que les auditeurs disent de Episode #11: Professor Allan Bradley - Founder and CEO of T-Therapeutics

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.